Logo image of IFRX

INFLARX NV (IFRX) Stock Fundamental Analysis

NASDAQ:IFRX - Nasdaq - NL0012661870 - Common Stock - Currency: USD

1.85  -0.06 (-3.14%)

Fundamental Rating

2

Taking everything into account, IFRX scores 2 out of 10 in our fundamental rating. IFRX was compared to 571 industry peers in the Biotechnology industry. The financial health of IFRX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, IFRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IFRX had negative earnings in the past year.
IFRX had a negative operating cash flow in the past year.
In the past 5 years IFRX always reported negative net income.
In the past 5 years IFRX always reported negative operating cash flow.
IFRX Yearly Net Income VS EBIT VS OCF VS FCFIFRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -71.38%, IFRX is not doing good in the industry: 65.90% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -87.13%, IFRX is in line with its industry, outperforming 49.56% of the companies in the same industry.
Industry RankSector Rank
ROA -71.38%
ROE -87.13%
ROIC N/A
ROA(3y)-33.59%
ROA(5y)-36.62%
ROE(3y)-39.44%
ROE(5y)-42.33%
ROIC(3y)N/A
ROIC(5y)N/A
IFRX Yearly ROA, ROE, ROICIFRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

IFRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IFRX Yearly Profit, Operating, Gross MarginsIFRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

IFRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IFRX has more shares outstanding
Compared to 5 years ago, IFRX has more shares outstanding
IFRX has a better debt/assets ratio than last year.
IFRX Yearly Shares OutstandingIFRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
IFRX Yearly Total Debt VS Total AssetsIFRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -1.94, we must say that IFRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.94, IFRX is in line with its industry, outperforming 52.93% of the companies in the same industry.
IFRX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
IFRX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: IFRX outperforms 42.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -1.94
ROIC/WACCN/A
WACC6.76%
IFRX Yearly LT Debt VS Equity VS FCFIFRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

IFRX has a Current Ratio of 5.31. This indicates that IFRX is financially healthy and has no problem in meeting its short term obligations.
IFRX has a Current ratio of 5.31. This is comparable to the rest of the industry: IFRX outperforms 55.95% of its industry peers.
A Quick Ratio of 4.61 indicates that IFRX has no problem at all paying its short term obligations.
IFRX has a Quick ratio of 4.61. This is comparable to the rest of the industry: IFRX outperforms 52.04% of its industry peers.
Industry RankSector Rank
Current Ratio 5.31
Quick Ratio 4.61
IFRX Yearly Current Assets VS Current LiabilitesIFRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for IFRX have decreased strongly by -40.00% in the last year.
Looking at the last year, IFRX shows a very strong growth in Revenue. The Revenue has grown by 177.15%.
EPS 1Y (TTM)-40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.77%
Revenue 1Y (TTM)177.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%103.95%

3.2 Future

The Earnings Per Share is expected to grow by 26.56% on average over the next years. This is a very strong growth
Based on estimates for the next years, IFRX will show a very strong growth in Revenue. The Revenue will grow by 81.75% on average per year.
EPS Next Y-22.14%
EPS Next 2Y-12.49%
EPS Next 3Y-0.24%
EPS Next 5Y26.56%
Revenue Next Year-93.22%
Revenue Next 2Y-58.4%
Revenue Next 3Y60.23%
Revenue Next 5Y81.75%

3.3 Evolution

IFRX Yearly Revenue VS EstimatesIFRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
IFRX Yearly EPS VS EstimatesIFRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IFRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IFRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IFRX Price Earnings VS Forward Price EarningsIFRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IFRX Per share dataIFRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.49%
EPS Next 3Y-0.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IFRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INFLARX NV

NASDAQ:IFRX (2/20/2025, 2:26:43 PM)

1.85

-0.06 (-3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-19 2025-03-19/amc
Inst Owners22.61%
Inst Owner Change6.03%
Ins Owners7.33%
Ins Owner ChangeN/A
Market Cap108.93M
Analysts85
Price Target8.77 (374.05%)
Short Float %0.76%
Short Ratio1.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.39%
Min EPS beat(2)-19.14%
Max EPS beat(2)-17.65%
EPS beat(4)1
Avg EPS beat(4)-14.18%
Min EPS beat(4)-45.04%
Max EPS beat(4)25.09%
EPS beat(8)5
Avg EPS beat(8)10.54%
EPS beat(12)8
Avg EPS beat(12)16.15%
EPS beat(16)10
Avg EPS beat(16)8.08%
Revenue beat(2)1
Avg Revenue beat(2)-21.86%
Min Revenue beat(2)-92.43%
Max Revenue beat(2)48.71%
Revenue beat(4)1
Avg Revenue beat(4)-60.19%
Min Revenue beat(4)-99.83%
Max Revenue beat(4)48.71%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.5%
EPS NQ rev (1m)1.96%
EPS NQ rev (3m)-16.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.5%
Revenue NQ rev (1m)-2.98%
Revenue NQ rev (3m)-93.78%
Revenue NY rev (1m)0.66%
Revenue NY rev (3m)20.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 619.53
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0
BVpS1.16
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.38%
ROE -87.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.59%
ROA(5y)-36.62%
ROE(3y)-39.44%
ROE(5y)-42.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.78%
Cap/Sales 38.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.31
Quick Ratio 4.61
Altman-Z -1.94
F-Score3
WACC6.76%
ROIC/WACCN/A
Cap/Depr(3y)15.64%
Cap/Depr(5y)29.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.77%
EPS Next Y-22.14%
EPS Next 2Y-12.49%
EPS Next 3Y-0.24%
EPS Next 5Y26.56%
Revenue 1Y (TTM)177.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%103.95%
Revenue Next Year-93.22%
Revenue Next 2Y-58.4%
Revenue Next 3Y60.23%
Revenue Next 5Y81.75%
EBIT growth 1Y-43.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year89.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.08%
OCF growth 3YN/A
OCF growth 5YN/A